Gilad Yosi

Gilad Yosi, Ph.D.

Assistant professor

(713) 798-6258

Email

yosi@bcm.edu

Positions

Assistant professor: Mol and Cell Biology
��
Houston, Texas

Staff scientist: Mol & Cell Biology-Mol.Regulation
��
Houston, TX, US

Education

Postdoctoral Training at Baylor college of medicine: Houston, Texas, United States

Postdoctoral Fellowship at Ariel University: Ariel, Israel

PhD from Bar Ilan University: 10/2015 - Ramat-Gan, Israel; Medicinal Chemistry

Professional Interests

Research interest

Professional Statement

My research focuses on understanding the role of steroid receptor coactivators (SRCs), particularly SRC-3, in regulatory T cell (Treg) and Th17 cell biology and function, with an emphasis on the translational implications of modulating SRC-3 activity in these T-cell populations for cancer and autoimmune diseases. My work integrates CRISPR-Cas9 genome editing, molecular and cellular immunology, and preclinical disease models to define the roles of SRCs in T-cell function and explore their potential as therapeutic targets.
A second line of my research focuses on drug combination strategies aimed at improving therapeutic outcomes in cancer, with particular interest in how small-molecule drug combinations modulate tumor immunology and the tumor–immune microenvironment.
More broadly, I am interested in bridging basic immunology and translational research to develop new therapeutic approaches for cancer immunotherapy, engineered T-cell therapies, and immune-mediated diseases.

Websites

full list of publications on google scholar

Selected Publications

Gilad Y., Firer M.A. and Gellerman G.. " Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells. " MDPI Biomedicines. 2016 ;
Gilad Y., Noy E., Senderowitz H., Albeck A., Firer M.A. and Gellerman G.. " Dual-drug RGD conjugates provide enhanced cytotoxicity of melanoma and non-small lung cancer cells. " Biopolymers: Peptide Science. 2016 ;
Gilad Y., Waintraub S., Albeck A. and Gellerman G.. " Synthesis of novel protected Nα(ω-Drug) amino acid building units for use in linear synthesis of peptide-drug conjugates. " Int J Pept Res Ther. 2016 ;
Gilad Y., Noy E., Senderowitz H., Albeck A., Firer M.A. and Gellerman G.. " Synthesis, biological studies and molecular dynamics of new anticancer RGD-based peptide conjugates for targeted drug delivery. " Bioorg. Med. Chem.. 2016 ;
Gilad Y., Firer M.A., Rozovsky A., Ragozin E., Redko B., Albeck A. and Gellerman G.. " "Switch off/switch on" regulation of drug cytotoxicity by conjugation to a cell targeting peptide. " EJMC. 2014 ;
Gellerman G., Baskin S., Galia L., Gilad Y. and Firer M.A.. " Drug resistance to chlorambucil in murine B-cell leukemic cells is overcome by its conjugation to a targeting peptide. " Anticancer Drugs. 2013 ;
Brider T., Gilad Y., Gellerman G.. " A fast entry to the novel medicinally-important 9-anilinoacridine peptidyls by solid phase organic synthesis (SPOS). " Tetrahedron Lett. 2011 ;
Y. Gilad, H. Tuchinsky, G. Ben-David, R. Minnes, Gancz, H. Senderowitz, G. Luboshits, M.A. Firer, G. Gellerman. " Discovery of potent molecular chimera (CM358) to treat human metastatic melanoma. " EJMC. 2017 Jul ;
Yosef Gilad, Sang Jun Han, David M Lonard. " " 2026 ;
Yosef Gilad, Adam M Dean, Yan Xia, Sang Jun Han, David M Lonard, Bert W O'Malley. " " 2025 ;
Sang Jun Han, Prashi Jain, Yosef Gilad, Yan Xia, Nuri Sung, Mi Jin Park, Adam M Dean, Rainer B Lanz, Jianming Xu, Clifford C Dacso, David M Lonard, Bert W O'Malley. " " PNAS. 2023 ;
Nuri Sung, Eunsu Kim, Yosef Gilad, Yuri Park, Adam M Dean, Yan Xia, Jianming Xu, Clifford C Dacso, David M Lonard, Sang Jun Han. " " 2026 ;
Yosef Gilad, David M Lonard. " " JBC. 2026 ;
Ortal Shimon, Adam M Dean, Shoshana Cohen, Aiden L Moser, Clifford C Dacso, Yosi Gilad, David M Lonard, Bert W O’Malley. " " Molecular immunology. 2025 ;

to edit your profile

��������